Patents by Inventor Marcel Bonn-Miller

Marcel Bonn-Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230414533
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 28, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20230364028
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: March 21, 2023
    Publication date: November 16, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11779549
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 10, 2023
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230059709
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by administering an effective amount of cannabidiol (CBD). Specifically, subjects having moderate to severe ASD and relatively high social avoidance and/or anxiety are more likely to show a reduction in irritability when treated with CBD.
    Type: Application
    Filed: October 20, 2022
    Publication date: February 23, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Joseph Palumbo, Stephen V. O'Quinn, Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230000790
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 5, 2023
    Applicants: ZYNERBA PHARMACEUTICALS, INC., ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11458110
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 4, 2022
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20220096396
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: September 2, 2021
    Publication date: March 31, 2022
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF FRAGILE X SYDROME WITH CANNABIDIOL
    Publication number: 20200360299
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 19, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile x syndrome with cannabidiol
    Patent number: 10758497
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: September 1, 2020
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20200214995
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of autism with cannabidiol
    Patent number: 10568848
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: February 25, 2020
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20200030255
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 30, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile X syndrome with cannabidiol
    Patent number: 10471022
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: November 12, 2019
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20190262280
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome ASD are treated in the subject.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 29, 2019
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of autism with cannabidiol
    Patent number: 10314792
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 11, 2019
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20190167605
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: January 16, 2019
    Publication date: June 6, 2019
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20190117588
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 25, 2019
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of fragile X syndrome with cannabidiol
    Patent number: 10213390
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: February 26, 2019
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree